Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this Perspective, the authors discuss the ethical challenges of individualized therapy (also called n-of-1) trials and argue that, although customized for the patient, these constitute ‘research’ nonetheless.
This Perspective discusses recent developments in NSCLC immunotherapy and targeted therapy, and highlights the key challenges and future directions for NSCLC management.
All countries worldwide have signed up to the United Nations Sustainable Development Goals and committed to the objective of achieving universal health coverage. Getting there will require understanding how packages of essential health services can be developed in resource-constrained settings and how experts and the public can make decisions about which health services should be provided free of charge.
Recent advances in computational and laboratory sciences are helping researchers to address large-scale sustained emergencies, such as the COVID-19 pandemic, and constantly adapt to the emergence of new questions, data and findings in order to synthesize real-time evidence that will inform policy decisions.
A comprehensive strategy for the next steps to ensure vaccination of the global population against SARS-CoV-2 is now required, and key steps and challenges are detailed in this Perspective.
PrEP is being incorporated into national HIV-prevention strategies in African countries, with key at-risk populations being prioritized. Expansion of these programs will require better access to and communication about these therapies.
The Cancer Core Europe centers share their experience on caring for patients with cancer during the COVID-19 pandemic ― a time of challenges and opportunities for cancer health professionals, researchers and patients alike.
The emerging success of neoadjuvant therapy is creating opportunities for understanding successful immune responses and improving therapies using this unique pool of knowledge.
The authors argue for a consistent weight-management approach, alongside an assessment of the risk for developing cardiometabolic diseases as a prevention strategy.
Amit and colleagues discuss where single-cell genomic technologies can be applied both in trial design and in the clinical trial stage to improve the development of immunotherapies.
Rare genetic diseases frequently involve a neuropsychiatric component for which a defined framework of investigation will expedite our understanding for these diseases as a whole.
In this Perspective, the authors present a framework, context and guidelines for accelerating the translation of machine-learning-based interventions in health care.